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Reply
We thank Goldsmith for his interest in our study; however, we disagree
with his interpretation of our results (1). The results reported in our
study were not derived from a subgroup analysis. Patients were
prospectively classified by the presence or absence of elevated central
pressures based on the relation between elevated filling pressures and
cardiac sympathetic activation (2). This was done to select a group with
underlying sympathetic activation because we hypothesized that
digoxin would be sympathoinhibitory in such patients. Furthermore,
because the heart failure groups were not combined, the statement
that digoxin had no effect on cardiac or total body norepinephrine
spillover in the heart failure group “as a whole” is not relevant. The
statistical analysis of the response to digoxin in the various groups is
also in no way problematic. Differences in group size and baseline
cardiac norepinephrine spillover were accounted for by the use of
general linear modeling procedures (MANOVA).
Goldsmith also suggests that our study is consistent with his
previous investigation (3) and that digoxin is neutral in terms of its
effects on sympathetic outflow because there was no change in total
body norepinephrine spillover. Our interpretation is that the total body
spillover index is insensitive to changes in specific vascular beds. The
potential for cardiac-specific responses to pharmacologic interven-
tions, without accompanying changes in total body spillover, has
recently been observed in another report from our laboratory (4).
Please recall that our study examined cardiac sympathetic responses to
digoxin. In both heart failure groups, the glycoside had clear effects on
cardiac norepinephrine spillover. It seems unreasonable, therefore, to
conclude that the effect of digoxin on cardiac sympathetic activity is
neutral.
Our investigation was a short-term study in well defined patients
with heart failure. The results of this investigation cannot be extrapo-
lated to the clinical use of long-term digoxin therapy in patients with
heart failure. These results provide insight into the complex mecha-
nism of action of digoxin and define a subset of severely ill patients in
whom a cardiac sympathoinhibitory effect may account for beneficial
responses to this agent. Interestingly, this short-term observation is
consistent with previous work demonstrating clinical responses to
digoxin in patients with a third heart sound (5) and a preliminary
report from the DIG study (6) showing greater benefit in subgroups of
patients with more severe heart failure.
GARY E. NEWTON, MD
JOHN D. PARKER, MD, FACC
Division of Cardiology
Department of Medicine
Mount Sinai Hospital
600 University Avenue
Suite 1609
Toronto, Ontario Canada M5G LX5
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Reimbursement for Cardiac
Rehabilitation Services
Subsequent to the publication of its initial Position Report on Cardiac
Rehabilitation in 1986 (1), the American College of Cardiology (ACC)
convened two ad hoc task forces to address supplemental areas for
cardiac rehabilitation. The 1990 task force reported on cardiac reha-
bilitation services after percutaneous transluminal coronary angio-
plasty (PTCA) and valvular surgery (2), and and the 1991 task force on
cardiac rehabilitation services after cardiac transplantation (3). These
ACC position papers outlined the potential benefits of cardiac reha-
bilitation for patients with these clinical problems that constituted the
basis for the College’s advocacy of cardiac rehabilitation services for
patients with these categories of cardiac illness.
Recently, the U.S. Health Care Financing Agency (HCFA) ap-
proved reimbursement for cardiac rehabilitation services for patients
after PTCA, after valve repair or valve replacement surgery and after
heart transplantation. The state chapters of the ACC, as well as
individual members and fellows of the College, should now urge
insurers other than Medicare carriers to extend approval for reim-
bursement for cardiac rehabilitation to these categories of patients.
NANETTE K. WENGER, MD, FACC
Emory University School of Medicine
69 Butler Street, SE
Atlanta, Georgia 30303
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